ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
46 Citations
268 Claims
- 1. (canceled)
-
2. (canceled)
-
3. (canceled)
-
4. (canceled)
-
5. (canceled)
-
6. (canceled)
-
7. (canceled)
-
8. (canceled)
-
9. (canceled)
-
10. (canceled)
-
11. (canceled)
-
12. (canceled)
-
13. (canceled)
-
14. (canceled)
-
15. (canceled)
-
16. (canceled)
-
17. (canceled)
-
18. (canceled)
-
19. (canceled)
-
20. (canceled)
-
21. (canceled)
-
22. (canceled)
-
23. (canceled)
-
24. (canceled)
-
25. (canceled)
-
26. (canceled)
-
27. (canceled)
-
28. (canceled)
-
29. (canceled)
-
30. (canceled)
-
31. (canceled)
-
32. (canceled)
-
33. (canceled)
-
34. (canceled)
-
35. (canceled)
-
36. (canceled)
-
37. (canceled)
-
38. (canceled)
-
39. (canceled)
-
40. (canceled)
-
41. (canceled)
-
42. (canceled)
-
43. (canceled)
-
44. (canceled)
-
45. (canceled)
-
46. (canceled)
-
47. (canceled)
-
48. (canceled)
-
49. (canceled)
-
50. (canceled)
-
51. (canceled)
-
52. (canceled)
-
53. (canceled)
-
54. (canceled)
-
55. (canceled)
-
56. (canceled)
-
57. (canceled)
-
58. (canceled)
-
59. (canceled)
-
60. (canceled)
-
61. (canceled)
-
62. (canceled)
-
63. (canceled)
-
64. (canceled)
-
65. (canceled)
-
66. (canceled)
-
67. (canceled)
-
68. (canceled)
-
69. (canceled)
-
70. (canceled)
-
71. (canceled)
-
72. (canceled)
-
73. (canceled)
-
74. (canceled)
-
75. (canceled)
-
76. (canceled)
-
77. (canceled)
-
78. (canceled)
-
79. (canceled)
-
80. (canceled)
-
81. (canceled)
-
82. (canceled)
-
83. (canceled)
-
84. (canceled)
-
85. (canceled)
-
86. (canceled)
-
87. (canceled)
-
88. (canceled)
-
89. (canceled)
-
90. (canceled)
-
91. (canceled)
-
92. (canceled)
-
93. (canceled)
-
94. (canceled)
-
95. (canceled)
-
96. (canceled)
-
97. (canceled)
-
98. (canceled)
-
99. (canceled)
-
100. (canceled)
-
101. (canceled)
-
102. (canceled)
-
103. (canceled)
-
104. (canceled)
-
105. (canceled)
-
106. (canceled)
-
107. (canceled)
-
108. (canceled)
-
109. (canceled)
-
110. (canceled)
-
111. (canceled)
-
112. (canceled)
-
113. (canceled)
-
114. (canceled)
-
115. (canceled)
-
116. (canceled)
-
117. (canceled)
-
118. (canceled)
-
119. (canceled)
-
120. (canceled)
-
121. (canceled)
-
122. (canceled)
-
123. (canceled)
-
124. (canceled)
-
125. (canceled)
-
126. (canceled)
-
127. (canceled)
-
128. (canceled)
-
129. (canceled)
-
130. (canceled)
-
131. (canceled)
-
132. (canceled)
-
133. (canceled)
-
134. (canceled)
-
136. (canceled)
-
137. (canceled)
-
138. (canceled)
-
139. An immunoconjugate comprising an anti-CD79b antibody comprising:
-
(i) an HVR-L1 sequence of KASOSVDYEGDSFLN (SEQ ID NO;
194)(ii) an HVR-L2 sequence of AASNLES (SEQ ID NO;
195)(iii) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO;
196)(iv) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO;
202)(v) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO;
203), and(vi) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO;
204),wherein said antibody is covalently attached to a cytotoxic agent. - View Dependent Claims (140, 260)
-
-
145. (canceled)
-
146. (canceled)
-
147. (canceled)
-
148. (canceled)
-
149. (canceled)
-
150. (canceled)
-
151. (canceled)
-
152. (canceled)
-
153. (canceled)
-
154. (canceled)
-
155. (canceled)
-
156. (canceled)
-
157. (canceled)
-
158. (canceled)
-
159. (canceled)
-
160. (canceled)
-
161. (canceled)
-
162. (canceled)
-
163. (canceled)
-
164. (canceled)
-
165. (canceled)
-
166. (canceled)
-
167. (canceled)
-
168. (canceled)
-
169. (canceled)
-
170. (canceled)
-
171. (canceled)
-
172. (canceled)
-
173. (canceled)
-
174. (canceled)
-
175. (canceled)
-
176. (canceled)
-
177. (canceled)
-
178. (canceled)
-
179. (canceled)
-
180. (canceled)
-
181. (canceled)
-
182. (canceled)
-
183. (canceled)
-
184. (canceled)
-
185. (canceled)
-
186. (canceled)
-
187. (canceled)
-
188. (canceled)
-
189. (canceled)
-
190. (canceled)
-
191. (canceled)
-
192. (canceled)
-
193. (canceled)
-
194. (canceled)
-
195. (canceled)
-
196. (canceled)
-
197. (canceled)
-
198. (canceled)
-
199. (canceled)
-
200. (canceled)
-
201. (canceled)
-
202. (canceled)
-
203. (canceled)
-
204. (canceled)
-
205. (canceled)
-
206. (canceled)
-
207. (canceled)
-
208. (canceled)
-
209. (canceled)
-
210. (canceled)
-
211. (canceled)
-
212. (canceled)
-
213. (canceled)
-
214. (canceled)
-
215. (canceled)
-
216. (canceled)
-
217. (canceled)
-
218. (canceled)
-
219. (canceled)
-
220. (canceled)
-
221. (canceled)
-
222. (canceled)
-
223. (canceled)
-
224. (canceled)
-
225. (canceled)
-
226. (canceled)
-
227. (canceled)
-
228. (canceled)
-
229. (canceled)
-
230. (canceled)
-
231. (canceled)
-
232. (canceled)
-
233. (canceled)
-
234. (canceled)
-
235. (canceled)
-
236. (canceled)
-
237. (canceled)
-
238. (canceled)
-
239. (canceled)
-
240. (canceled)
-
241. (canceled)
-
242. (canceled)
-
243. (canceled)
-
244. (canceled)
-
245. (canceled)
-
246. (canceled)
-
247. (canceled)
-
248. (canceled)
-
249. (canceled)
-
250. (canceled)
-
251. (canceled)
-
252. (canceled)
-
253. (canceled)
-
254. (canceled)
-
255. (canceled)
-
256. (canceled)
-
257. (canceled)
-
258. (canceled)
Specification